SINOMED(SH:688108) Zheng Quan Zhi Xing·2025-08-13 11:20Core Viewpoint - The stock of Sino Medical Technology Co., Ltd. has experienced significant abnormal fluctuations, with a cumulative price increase of 100% over five consecutive trading days, prompting the company to issue a notice regarding the situation [1][4][5]. Stock Trading Abnormalities - The stock price of Sino Medical increased by 30% over three consecutive trading days from August 11 to August 13, 2025 [1][4]. - The closing price on August 13, 2025, was 29.50 yuan per share, with the recent price increase surpassing that of most peers in the industry and the Shanghai Composite Index [2][7]. - The rolling price-to-earnings (P/E) ratio of the company is 1701.41, significantly deviating from the industry average P/E ratio of 33.59 [2][7]. Company Disclosures - The company has disclosed that it received conditional approval from the FDA for a new drug-eluting stent system on July 22, 2025, and a breakthrough medical device designation for its COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter on August 7, 2025 [1][3][5]. - The breakthrough designation by the FDA provides priority review and support for product development and clinical trials, although it does not guarantee subsequent approval for market entry [3][8]. Shareholder and Control Information - The company confirmed that there are no undisclosed significant matters affecting stock trading, including major asset restructuring or debt restructuring, as of the announcement date [2][5][6]. - The company’s major shareholders and actual controllers have not reported any significant events that could influence stock trading [2][5].